Preventive chemotherapy in human helminthiasis : coordinated use of anthelminthic drugs in control interventions : a manual for health professionals and programme managers.
Saved in:
| Corporate Author: | |
|---|---|
| Format: | Book |
| Published: |
Geneva, Swizterland :
World Health Organization,
2006.
|
| Subjects: | |
| Online Access: | Visit NHRC Library Visit NHRC Library |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- 1. Meeting the challenge
- 2. Situation analysis
- 3. Preventive chemotherapy and its role in the control of helminthiasis
- 3.1 Aim and rationale
- 3.2 Ancillary benefits and advantages of preventive chemotherapy
- 4. WHO-recommended drugs: alone and in combination
- 5. Preventive chemotherapy: best practice
- 5.1 Eligibility and ineligibility for treatment
- 5.2 Safety and adverse reactions
- 5.2.1 Safety of drug combinations for treatment of helminth infections
- 5.2.2 Safety in pregnancy
- 5.3 Drug quality
- 5.4 Programme implementation
- 5.4.1 Drug delivery and incorporation into established and novel programmes
- 5.4.2 Implementation charts--how to intervene
- 5.5 Different age groups and special risk groups in preventive chemotherapy
- 5.5.1 Preschool children (aged 1-5 years)
- 5.5.2 School-age children (aged 6-15 years) and adults (aged >15 years)
- 5.5.3 Adolescent girls, women of reproductive age and pregnant women
- 5.6 Problems caused by concurrent infections
- 6. Measuring and monitoring during preventive chemotherapy
- 6.1 Coverage
- 6.2 Evaluation of impact on morbidity and transmission
- 6.3 Threat of drug resistance and monitoring of drug efficacy
- Annexes
- I. Occurrence of lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiasis and loiasis in countries and territories where preventive chemotherapy interventions may need to be implemented
- II. Rapid assessment and decision charts for schistosomiasis and soil-transmitted helminthiasis
- III. Standardized form for recording serious adverse experiences
- IV. Drug supply, recommended dosages and dose poles
- V. Coverage forms
- VI. Disease-specific information